


AChE-IN-28

Cat. No.:	HY-151927
Molecular Formula:	C ₃₃ H ₄₈ BrF ₃ N ₅ O ₄
Molecular Weight:	715.66
Target:	Cholinesterase (ChE)
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AChE-IN-28 (Compound 2h) is a selective slow-binding inhibitor of acetylcholinesterase with an IC ₅₀ of 0.2 nM ^[1] .	
IC₅₀ & Target	AChE 0.2 nM (IC ₅₀)	
In Vivo	AChE-IN-28 (Compound 2h) (0.005-0.1 mg/kg; i.p.; single dose) ameliorates symptoms of myasthenia gravis in rats. The LD ₅₀ is 10 mg/kg in mice (i.p.) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female Wistar rats, experimental autoimmune model of myasthenia gravis (EAMG) ^[1]
	Dosage:	0.005, 0.01, 0.015 and 0.1 mg/kg
	Administration:	Intraperitoneal injection, single dose
	Result:	The dose that restored the value of decrement of amplitude of APs in animals with EAMG to the level of control rats was 0.01 mg/kg. Showed a long lasting effect and had no significant effect on the force of urinary bladder contractions in animals with EAMG.

REFERENCES

[1]. Saifina LF, et al. Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning. *Eur J Med Chem.* 2022 Nov 24;246:114949.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA